Wolfe Research last night downgraded Intellia Therapeutics (NTLA) to Peer Perform from Outperform without a price target The safety issue for nexiguran ziclumeran hinders the bull thesis, the analyst tells investors in a research note. The firm expects the stock “to become fragile as investors will likely be intolerant of the FDA hold.” Wolfe now sees no fundamental reason to drive the stock higher.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia Therapeutics downgraded to Peer Perform from Outperform at Wolfe Research
- FDA appoints Richard Pazdur as Director of CDER
- Intellia Therapeutics downgraded to Hold from Buy at JonesResearch
- Intellia Therapeutics downgraded to In Line from Outperform at Evercore ISI
- Intellia Reports Favorable Phase 1 Data for Nex-Z